IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA

Inclusion criteria

• Patient is undergoing a revision total knee arthroplasty where in the opinion of the investigator, the patient's existing tibial component excludes the tibial tubercle as a valid intraosseous injection site.
• Patient is able to understand the study design and intervention and gives informed consent to participate in the study.
• Age > 18 years.

Exclusion criteria

• Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc).
• Patient received or is scheduled to receive intravenous Vancomycin within 7 days prior to their planned revision procedure.
• Any hardware, condition, or anatomic status that prevents the medial malleolus from being a viable intraosseous injection site.
• Refusal to participate
• Any condition, in the opinion of the primary investigator, that deems the participant unsuitable for participation in the research study.